New data for KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
Tarcocimab Tedromer (KSI-301) 5 mg for the Treatment of wAMD: One-Year Primary Efficacy and Safety Outcomes of the Phase 3 DAYLIGHT Study
By
X
1250 Page Mill Road Palo Alto, CA 94304 United States of America